Revive’s bioinformatics platform was specifically designed to identify repurposed and innovative drug treatments for serious and unmet medical needs. The company reviews scientific literature looking for mechanisms of action that could prove useful for diseases.

We then rank these drug-disease pairs based on a weighting system that incorporates clinical studies, FDA correspondence, competition, and unmet medical need. 

To date, Revive has identified a number of repurposed drug and plant-derived candidates, such as cannabinoids, that warrant further screening. We are currently focusing our research on cannabis-derived or cannabis-related drug candidates, including CBD and THC derivatives.

We believe this strategy offers the potential for development of highly differentiated drug candidates that are superior to current standards of care, as well as new intellectual property through the combination of repurposed drug candidates and cannabis-related drug candidates.

---